Hikma Pharmaceuticals plc (LON:HIK) (NASDAQ Dubai:HIK) (OTC:HKMPY) announced on Thursday the approval of KLOXXADO (naloxone HCl) Nasal Spray 8 mg by Health Canada for treating opioid overdoses in adult patients.
The nasal spray delivers 8 mg of naloxone hydrochloride per dose to reverse opioid overdose effects, such as respiratory and central nervous system depression.
Under a six-year commercial agreement, Emergent BioSolutions Inc (NASDAQ:EBS) will lead the marketing and sales of KLOXXADO in Canada, where it aims to increase access to intranasal naloxone. Emergent will work with Canadian agencies and private payers to make KLOXXADO available by prescription as early as 2026.
Hikma will continue to manufacture KLOXXADO at its Columbus, Ohio facility and supply it exclusively to Emergent for commercialisation. The approval of KLOXXADO Nasal Spray comes at a time when Health Canada has reported a decrease in overdose deaths, partly attributed to expanded naloxone distribution.
Genentech's fenebrutinib meets primary endpoint in pivotal Phase III study for multiple sclerosis
Gemma Biotherapeutics doses first parent in GB221 Phase 1/2 CHARISMA clinical trial
Lario Therapeutics awarded USD2.4m in grants for neuronal calcium channel research
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Insilico Medicine signs co-development collaboration agreement with Hygtia Therapeutics
Orsini chosen as specialty pharmacy partner for ITVISMA (onasemnogene abeparvovec-brve)
Hemispherian secures US patent allowance expanding GLIX1 patent protection
MavriX Bio reports first patient dosed in Phase 1/2 trial of MVX-220 for AS
Precision NeuroMed's glioblastoma multiforme treatment granted FDA Orphan Drug Designation